Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDA Orange Book
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. Vx-661
1. Vx-661
2. 1152311-62-0
3. Tezacaftor (vx-661)
4. Tezacaftor [usan]
5. (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide
6. Vx661
7. Vx 661
8. 8rw88y506k
9. 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-{1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl}cyclopropane-1-carboxamide
10. Unii-8rw88y506k
11. 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide
12. Cv6
13. Cyclopropanecarboxamide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-(1-((2r)-2,3-dihydroxypropyl)-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1h-indol-5-yl)-
14. Tezacaftor [mi]
15. Tezacaftor [inn]
16. Tezacaftor (usan/inn)
17. Tezacaftor [who-dd]
18. Schembl322362
19. Vx 661;vx661;tezacaftor
20. Chembl3544914
21. Schembl10034144
22. Tezacaftor [orange Book]
23. Gtpl10199
24. Dtxsid40673070
25. Bdbm281054
26. Symkevi Component Tezacaftor
27. Bcp07173
28. Cyclopropanecarboxamide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1h-indol-5-yl]-
29. Ex-a1759
30. Trikafta Component Tezacaftor
31. Mfcd23106064
32. S7059
33. Us10022352, Compound 315
34. Zinc68206930
35. Ccg-269854
36. Cs-1078
37. Db11712
38. Tezacaftor Component Of Trikafta
39. 1-(2,2-difluoro-2h-1,3-benzodioxol-5-yl)-n-{1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl}cyclopropane-1-carboxamide
40. Ac-32773
41. As-35211
42. Hy-15448
43. Example 315 [us20090131492a1]
44. Sw219937-1
45. D11041
46. A857959
47. Q27270940
48. (r)-1 (2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide
49. (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropane-1-carboxamide
50. 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-~{n}-[1-[(2~{r})-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide
51. 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-(1-((2r)-2,3-dihydroxypropyl)-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1h-indol-5-yl)cyclopropanecarboxamide
52. 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1h-indol-5-yl]-cyclopropanecarboxamide
53. Vx661; Vx 661; Tezacaftor;(r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide
Molecular Weight | 520.5 g/mol |
---|---|
Molecular Formula | C26H27F3N2O6 |
XLogP3 | 2.9 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 8 |
Exact Mass | 520.18212107 g/mol |
Monoisotopic Mass | 520.18212107 g/mol |
Topological Polar Surface Area | 113 Ų |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 858 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Tezacaftor is combined with ivacaftor in one product for the treatment of cystic fibrosis (CF) in patients aged 12 years or older with two copies of the _F508del_ gene mutation or at least one mutation in the CFTR gene that is responsive to this drug. Tezacaftor, when used in combination with ivacaftor and [elexacaftor] in the product Trikafta, is also indicated for the treatment of CF in patients 12 years of age and older that have at least one _F508del_ mutation in the CFTR gene.
FDA Label
Clinical studies have shown a significant decrease in sweat chloride and an increase in the forced expiratory volume (FEV), a measure of lung function, following Tevacaftor/Ivacaftor therapy. Phase 3 clinical studies have shown that a significant increase in forced expiratory volume was attained at 4 and 8 weeks after initiating this drug. The above effects lead to improvement of the respiratory symptoms of cystic fibrosis. Tezacaftor does not induce clinically significant QT prolongation. When given with ivacaftor, tezacaftor can lead to liver transaminase elevations. Testing of transaminases (ALT and AST) levels should occur before starting this combination every 3 months during the first year of treatment, and every year afterwards. Patients with a history of transaminase elevations should be monitored more frequently.
Absorption
The Cmax, Tmax and AUC of tezacaftor, when administered with ivacaftor, are 5.95 mcg/ml, 2-6 h, and 84.5 mcg.h/ml respectively. Exposure of tezacaftor/ivacaftor increases 3-fold when it is administered with a high-fat meal.
Route of Elimination
After oral administration, the majority of tezacaftor dose (72%) is found excreted in the feces either unchanged or as its metabolite, M2. About 14% of the administered dose is found excreted in the urine as the metabolite, M2. It was noted that less than 1% of the administered dose is excreted unchanged in the urine and thus, renal excretion is not the major elimination pathway.
Volume of Distribution
The apparent volume of distribution of tezacaftor was 271 L in a study of patients in the fed state who received 100 mg of tezacaftor every 12 hours.
Clearance
The apparent clearance of tezacaftor has been measured at 1.31 L/h for patients in the fed state during a clinical trial.
Tezacaftor is metabolized extensively in humans by the action of CYP3A4 and CYP3A5. There are three main circulating metabolites; M1, M2, and M5. The M1 is an active metabolite with similar activity to the parent drug, tezacaftor. The M2 metabolite is significantly less active and M5 is considered an inactive metabolite. An additional circulating metabolite, M3, corresponding to the glucuronide form of tezacaftor.
The apparent half-life of tezacaftor is approximately 57.2 hours.
The transport of charged ions across cell membranes is normally achieved through the actions of the cystic fibrosis transmembrane regulator (CFTR) protein. This protein acts as a channel and allows for the passage of chloride and sodium. This process affects the movement of water in and out of the tissues and impacts the production of mucus that lubricates and protects certain organs and body tissues, including the lungs. In the _F508del_ mutation of the CFTR gene, one amino acid is deleted at the position 508, therefore, the CFTR channel function is compromised, resulting in thickened mucus secretions. CFTR correctors such as tezacaftor aim to repair F508del cellular misprocessing. This is done by modulating the position of the CFTR protein on the cell surface to the correct position, allowing for adequate ion channel formation and increased in water and salt movement through the cell membrane. The concomitant use of ivacaftor is intended to maintain an open channel, increasing the transport of chloride, reducing thick mucus production.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-11-10
Pay. Date : 2021-09-09
DMF Number : 36280
Submission : 2021-09-14
Status : Active
Type : II
NDC Package Code : 59651-618
Start Marketing Date : 2024-01-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (40kg/50kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
GDUFA
DMF Review : Complete
Rev. Date : 2021-11-10
Pay. Date : 2021-09-09
DMF Number : 36280
Submission : 2021-09-14
Status : Active
Type : II
NDC Package Code : 59651-618
Start Marketing Date : 2024-01-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (40kg/50kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 57572-0724
Start Marketing Date : 2024-04-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 57572-0719
Start Marketing Date : 2021-05-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 50909-1903
Start Marketing Date : 2021-02-08
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (0.8kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 24538-661
Start Marketing Date : 2018-02-12
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
About the Company : Medichem is an indepently-owned company based in Barcelona. Founded in 1972 and with more than 45 years, Medichem has been engaged in the process development and manufacture of Act...
About the Company : Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company comme...
About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...
About the Company : Laurus Labs is a leading research and development-driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of Active Ph...
About the Company : Prague Scientific has decades of experience in developing, producing and distributing medicines. It is a cost leader in urology, cardiology, oncology and pain products, with specia...
About the Company : ScinoPharm Taiwan Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a w...
Details:
VX-121/VX-661/VX-561 (vanzacaftor/tezacaftor/deutivacaftor) is a combination of three CFTR modulators. It is being evaluated in phase 3 clinial trials for the treatment of Cystic Fibrosis.
Lead Product(s): Vanzacaftor,Tezacaftor,Deutivacaftor
Therapeutic Area: Genetic Disease Brand Name: VX-121
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2024
Lead Product(s) : Vanzacaftor,Tezacaftor,Deutivacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vertex Gets FDA Acceptance for Vanzacaftor/Tezacaftor/Deutivacaftor for Cystic Fibrosis
Details : VX-121/VX-661/VX-561 (vanzacaftor/tezacaftor/deutivacaftor) is a combination of three CFTR modulators. It is being evaluated in phase 3 clinial trials for the treatment of Cystic Fibrosis.
Brand Name : VX-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 02, 2024
Details:
VX-121/VX-661/VX-561 (vanzacaftor/tezacaftor/deutivacaftor) is a combination of three CFTR modulators. It is being evaluated in phase 3 clinial trials for the treatment of Cystic Fibrosis.
Lead Product(s): Vanzacaftor,Tezacaftor,Deutivacaftor
Therapeutic Area: Genetic Disease Brand Name: VX-121
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Lead Product(s) : Vanzacaftor,Tezacaftor,Deutivacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vertex Announces Positive Results from Pivotal Trials for Cystic Fibrosis
Details : VX-121/VX-661/VX-561 (vanzacaftor/tezacaftor/deutivacaftor) is a combination of three CFTR modulators. It is being evaluated in phase 3 clinial trials for the treatment of Cystic Fibrosis.
Brand Name : VX-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 05, 2024
Details:
Kaftrio (ivacaftor/tezacaftor/elexacaftor) is an oral medicine designed to binding to different sites on the CFTR protein, which is investigated for the treatment of cystic fibrosis in patients aged 2 years & above.
Lead Product(s): Ivacaftor,Tezacaftor,Elexacaftor
Therapeutic Area: Genetic Disease Brand Name: Kaftrio
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2023
Lead Product(s) : Ivacaftor,Tezacaftor,Elexacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Kaftrio (ivacaftor/tezacaftor/elexacaftor) is an oral medicine designed to binding to different sites on the CFTR protein, which is investigated for the treatment of cystic fibrosis in patients aged 2 years & above.
Brand Name : Kaftrio
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 24, 2023
Details:
Kaftrio (ivacaftor/tezacaftor/elexacaftor) is an oral medicine designed to binding to different sites on the CFTR protein, which is investigated for the treatment of cystic fibrosis in patients aged 2 years & above.
Lead Product(s): Ivacaftor,Tezacaftor,Elexacaftor
Therapeutic Area: Genetic Disease Brand Name: Kaftrio
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2023
Lead Product(s) : Ivacaftor,Tezacaftor,Elexacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children...
Details : Kaftrio (ivacaftor/tezacaftor/elexacaftor) is an oral medicine designed to binding to different sites on the CFTR protein, which is investigated for the treatment of cystic fibrosis in patients aged 2 years & above.
Brand Name : Kaftrio
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 23, 2023
Details:
Trikafta is a combination drug where elexacaftor and tezacaftor bind to different sites of CFTR and additionally facilitates the cellular processing and trafficking of mutated CFTR. Ivacaftor potentiates the channel open probability of the CFTR protein at the cell surface.
Lead Product(s): Elexacaftor,Tezacaftor,Ivacaftor
Therapeutic Area: Genetic Disease Brand Name: Trikafta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Lead Product(s) : Elexacaftor,Tezacaftor,Ivacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)...
Details : Trikafta is a combination drug where elexacaftor and tezacaftor bind to different sites of CFTR and additionally facilitates the cellular processing and trafficking of mutated CFTR. Ivacaftor potentiates the channel open probability of the CFTR protein a...
Brand Name : Trikafta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 26, 2023
Details:
TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), is prescription medicine for treatment of cystic fibrosis. Based on analysis through Week 144 of 192-week study, people receiving TRIKAFTA maintained improvement in lung function, respiratory symptom and CFTR function.
Lead Product(s): Elexacaftor,Tezacaftor,Ivacaftor
Therapeutic Area: Genetic Disease Brand Name: Trikafta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Lead Product(s) : Elexacaftor,Tezacaftor,Ivacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), is prescription medicine for treatment of cystic fibrosis. Based on analysis through Week 144 of 192-week study, people receiving TRIKAFTA maintained improvement in lung function, respiratory sym...
Brand Name : Trikafta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 03, 2022
Details:
TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) real-world safety and effectiveness interim results show improved lung function and significant reductions in risk of pulmonary exacerbations, lung transplant and death for people with cystic fibrosis (CF).
Lead Product(s): Ivacaftor,Tezacaftor,Elexacaftor
Therapeutic Area: Genetic Disease Brand Name: Trikafta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Lead Product(s) : Ivacaftor,Tezacaftor,Elexacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) real-world safety and effectiveness interim results show improved lung function and significant reductions in risk of pulmonary exacerbations, lung transplant and death for people with cystic fi...
Brand Name : Trikafta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 10, 2022
Details:
TRIKAFTA is an oral medicine designed to increase quantity and function of CFTR protein at cell surface, is a prescription medicine used for treatment of cystic fibrosis in patients ages 6 years and older who have at least one copy of F508del mutation in CFTR gene.
Lead Product(s): Elexacaftor,Tezacaftor,Ivacaftor
Therapeutic Area: Genetic Disease Brand Name: Trikafta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Lead Product(s) : Elexacaftor,Tezacaftor,Ivacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ...
Details : TRIKAFTA is an oral medicine designed to increase quantity and function of CFTR protein at cell surface, is a prescription medicine used for treatment of cystic fibrosis in patients ages 6 years and older who have at least one copy of F508del mutation in...
Brand Name : Trikafta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 20, 2022
Details:
TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) was approved by the Australian Therapeutic Goods Administration (TGA) in March 2021 based on the results of four global Phase 3 clinical trials, which included multiple Australian trial sites and patients.
Lead Product(s): Elexacaftor,Tezacaftor,Ivacaftor
Therapeutic Area: Genetic Disease Brand Name: Trikafta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Australian Pharmaceutical Benefits Scheme
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 27, 2022
Lead Product(s) : Elexacaftor,Tezacaftor,Ivacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Australian Pharmaceutical Benefits Scheme
Deal Size : Undisclosed
Deal Type : Agreement
Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivaca...
Details : TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) was approved by the Australian Therapeutic Goods Administration (TGA) in March 2021 based on the results of four global Phase 3 clinical trials, which included multiple Australian trial sites an...
Brand Name : Trikafta
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 27, 2022
Details:
EC approval for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor has shown clinical benefit for people with CF ages 12 and above. This medicine is also approved in the regulatory authorities of New Zealand and Switzerland, where it is known as TRIKAFTA.
Lead Product(s): Ivacaftor,Tezacaftor,Elexacaftor
Therapeutic Area: Genetic Disease Brand Name: Kaftrio
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2022
Lead Product(s) : Ivacaftor,Tezacaftor,Elexacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivac...
Details : EC approval for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor has shown clinical benefit for people with CF ages 12 and above. This medicine is also approved in the regulatory authorities of New Zealand and Switzerland, where i...
Brand Name : Kaftrio
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 11, 2022
2-Bromo-5-fluoro-4-nitroaniline
CAS Number : 952664-69-6
End Use API : Tezacaftor
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...
CAS Number : 3587-60-8
End Use API : Tezacaftor
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...
2-methyl-4-(trimethylsilyl)but-3-yn-2-ol
CAS Number : 5272-33-3
End Use API : Tezacaftor
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...
Regulatory Info :
Registration Country : Norway
Ivakaftor; Tezakaftor; Eleksakaftor
Brand Name : Cafe trio
Dosage Form : Granules in a dose bag
Dosage Strength : 75 mg/50 mg/100 mg
Packaging : Dosepose 4 7item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Ivakaftor; Tezakaftor; Eleksakaftor
Brand Name : Cafe trio
Dosage Form : Granules in a dose bag
Dosage Strength : 60 mg/40 mg/80 mg
Packaging : Dosepose 4 7item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Elexacaftorum; Tezacaftorum; Ivacaftorum
Brand Name : Trikafta
Dosage Form : Filmtabl
Dosage Strength : 100mg/50mg/75mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Elexacaftorum; Tezacaftorum; Ivacaftorum
Brand Name : Trikafta
Dosage Form : Filmtabl
Dosage Strength : 50mg/25mg/37.5mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Symdeko
Dosage Form : Filmtabl
Dosage Strength : 100mg/150mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Global Sales Information
Market Place
ABOUT THIS PAGE
A Tezacaftor manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tezacaftor, including repackagers and relabelers. The FDA regulates Tezacaftor manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tezacaftor API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tezacaftor manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tezacaftor supplier is an individual or a company that provides Tezacaftor active pharmaceutical ingredient (API) or Tezacaftor finished formulations upon request. The Tezacaftor suppliers may include Tezacaftor API manufacturers, exporters, distributors and traders.
click here to find a list of Tezacaftor suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tezacaftor DMF (Drug Master File) is a document detailing the whole manufacturing process of Tezacaftor active pharmaceutical ingredient (API) in detail. Different forms of Tezacaftor DMFs exist exist since differing nations have different regulations, such as Tezacaftor USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tezacaftor DMF submitted to regulatory agencies in the US is known as a USDMF. Tezacaftor USDMF includes data on Tezacaftor's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tezacaftor USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tezacaftor suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tezacaftor as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tezacaftor API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tezacaftor as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tezacaftor and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tezacaftor NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tezacaftor suppliers with NDC on PharmaCompass.
Tezacaftor Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tezacaftor GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tezacaftor GMP manufacturer or Tezacaftor GMP API supplier for your needs.
A Tezacaftor CoA (Certificate of Analysis) is a formal document that attests to Tezacaftor's compliance with Tezacaftor specifications and serves as a tool for batch-level quality control.
Tezacaftor CoA mostly includes findings from lab analyses of a specific batch. For each Tezacaftor CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tezacaftor may be tested according to a variety of international standards, such as European Pharmacopoeia (Tezacaftor EP), Tezacaftor JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tezacaftor USP).
LOOKING FOR A SUPPLIER?